The study met the primary endpoint, demonstrating a complete response of 89% in the ondansetron extended release injection arm vs 82% in the standard ondansetron injection arm. Topline data were ...
The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. ("Artisan") and Tulex Pharmaceuticals ("Tulex" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback